b
Thank You！
Your requirement has been sent, we will contact you quickly!
Sent Failed！
Try again!
Synonymous： | Alogliptin |
CAS： | 850649-62-6 |
Molecular Formula： | C18H21N5O2C7H6O2 |
Molecular Weight： | 461.51 |
Appearance | white powder |
Storage | Room temperature storage |
Category | Treatment of type II diabetes mellitus |
Incretin is a peptide hormone produced by gastrointestinal tract after meal, which can promote islet growth β Cells secrete insulin, It includes glucagon like peptide-1 (GLP-1 and Glucose dependent insulinotropic peptide (GIP) secretion from L cells and duodenal K cells in ileum and colon respectively. GLP-1 and GIP can release into the blood circulation within minutes after taking food, but are rapidly inactivated by serine protease DPP-4. In type 2 diabetes patients, the level of incretin insulin in the body decreases significantly, thus preventing incretin inactivation. Time will effectively reduce blood sugar. As a DPP-4 inhibitor, agliptin benzoate can selectively inhibit DPP-4, reduce the inactivation of GLP-1 in vivo, increase the level of GLP-1 in vivo, and reduce blood glucose. When the blood glucose drops to the normal level, it will not continue to play a hypoglycemic role, so it can effectively reduce the risk of hypoglycemia. In addition, DPP-4 inhibitor can delay gastric emptying, increase satiety, inhibit appetite and help patients reduce body weight. Therefore, these drugs can effectively reduce blood sugar, but also reduce the risk of hypoglycemia and body weight gain, overcome the obstacles of patients reaching the standard, and bring new hope to the treatment of diabetes.
A Glenn Dean's single drug therapy or combination with other hypoglycemic drugs is usually well tolerated in type 2 diabetic patients with poor glycemic control. The risk of hypoglycemia caused by the drug is low, which is ≤ 8.3% in the agliptin treatment group and ≤ 10.5% in the placebo group, respectively, and there is no significant difference between young and elderly patients. The long-term safety of agliptin remains to be investigated in clinical practice and clinical research.
The most common adverse reactions of agliptin benzoate were nasopharyngitis, headache and upper respiratory tract infection. Most adverse reactions were mild to moderate and had no correlation with dose.
Manufacturing
